Anthropic Biology Discovery Draws Cautious Notes From Scientists
THE SO WHAT
The pushback on Anthropic’s enzyme discovery claim is a reminder that AI-for-bio will be judged on wet-lab validation, not model narratives. If you’re building in this space, budget time and money for independent replication or your “breakthroughs” won’t move regulators, partners, or acquirers.
READ THE SOURCE
MORE FROM THE WIRE
Applied AIAnthropic commits to spending $11.6B over seven years on Akamai cloud services and secures an option to take a stake of up to 5%; AKAM jumps 17%+ after hours
LLM demand is now underwriting alternative cloud-scale providers—$11.6B over seven years plus equity optionality turns Akamai into a serious AI infra counterweight. If you’re a large AI buyer, this is a template: trade long-term spend commitments for better economics and strategic influence.
White House asks OpenAI and Anthropic to hold new models from UK testers until US review, sources say.
US regulators asking labs to pause sharing new models with UK testers puts geopolitics directly into your model evaluation roadmap. If you operate across jurisdictions, assume staggered access to frontier models and design your testing, compliance, and launch plans for regulatory sequencing, not global simultaneity.
Applied AIAnthropic signs $11.6bn Akamai cloud deal and gets warrant for 5% of Akamai
The $11.6B, seven-year Akamai deal—expandable to ~$20B—plus a warrant for 7.7M shares shows labs are locking in infra with equity-style upside, not just volume discounts. If you’re a cloud or colo provider, expect large AI customers to negotiate for cap table exposure alongside capacity.
Applied AIThe AI commerce era: 7 e-commerce leaders on what’s still broken
The constraint in AI commerce isn’t more plugins, it’s orchestration—an infra layer where agents can own workflows end to end. If you run e‑com, start mapping the few workflows where you’d actually let an agent touch inventory, pricing, or ad spend and design guardrails there, not across the whole stack.